Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer

Tumor-infiltrating B lymphocytes assemble in clusters, undergoing B-cell receptor–driven activation, proliferation, and isotype switching. Clonally expanded, IgG isotype-biased humoral immunity associates with favorable prognosis primarily in triple-negative breast cancers. In breast cancer, humoral immune responses may contribute to clinical outcomes, especially in more immunogenic subtypes. Here, we investigated B lymphocyte subsets, immunoglobulin expression, and clonal features in breast tumors, focusing on aggressive triple-negative breast cancers (TNBC). In samples from patients with TNBC and healthy volunteers, circulating and tumor-infiltrating B lymphocytes (TIL-B) were evaluated. CD20+CD27+IgD− isotype-switched B lymphocytes were increased in tumors, compared with matched blood. TIL-B frequently formed stromal clusters with T lymphocytes and engaged in bidirectional functional cross-talk, consistent with gene signatures associated with lymphoid assembly, costimulation, cytokine–cytokine receptor interactions, cytotoxic T-cell activation, and T-cell–dependent B-cell activation. TIL-B–upregulated B-cell receptor (BCR) pathway molecules FOS and JUN, germinal center chemokine regulator RGS1, activation marker CD69, and TNFα signal transduction via NFκB, suggesting BCR–immune complex formation. Expression of genes associated with B lymphocyte recruitment and lymphoid assembly, including CXCL13, CXCR4, and DC-LAMP, was elevated in TNBC compared with other subtypes and normal breast. TIL-B–rich tumors showed expansion of IgG but not IgA isotypes, and IgG isotype switching positively associated with survival outcomes in TNBC. Clonal expansion was biased toward IgG, showing expansive clonal families with specific variable region gene combinations and narrow repertoires. Stronger positive selection pressure was present in the complementarity determining regions of IgG compared with their clonally related IgA in tumor samples. Overall, class-switched B lymphocyte lineage traits were conspicuous in TNBC, associated with improved clinical outcomes, and conferred IgG-biased, clonally expanded, and likely antigen-driven humoral responses. Significance: Tumor-infiltrating B lymphocytes assemble in clusters, undergoing B-cell receptor–driven activation, proliferation, and isotype switching. Clonally expanded, IgG isotype-biased humoral immunity associates with favorable prognosis primarily in triple-negative breast cancers. Graphical Abstract

[1]  Mirjana Efremova,et al.  CellPhoneDB: inferring cell–cell communication from combined expression of multi-subunit ligand–receptor complexes , 2020, Nature Protocols.

[2]  P. Tan,et al.  Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers , 2020, Breast Cancer Research and Treatment.

[3]  Jeffrey E. Lee,et al.  B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.

[4]  E. Winer,et al.  Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[5]  David L. Marron,et al.  B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer , 2019, Cell.

[6]  D. Larsimont,et al.  Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. , 2019, JCI insight.

[7]  Jun S. Liu,et al.  Landscape of B cell immunity and related immune evasion in human cancers , 2018, Nature Genetics.

[8]  D. Larsimont,et al.  Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer , 2018, Front. Immunol..

[9]  L. Pusztai,et al.  Immunological differences between primary and metastatic breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  F. Luciani,et al.  High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes , 2018, bioRxiv.

[11]  Sean C. Bendall,et al.  A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging , 2018, Cell.

[12]  Ambrose J. Carr,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.

[13]  A. Tutt,et al.  Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer , 2018, Clinical Cancer Research.

[14]  L. Villa,et al.  B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses , 2018, PloS one.

[15]  M. Uguccioni,et al.  Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis , 2018, Arthritis Research & Therapy.

[16]  Franca Fraternali,et al.  BRepertoire: a user-friendly web server for analysing antibody repertoire data , 2018, Nucleic Acids Res..

[17]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[18]  U. de Faire,et al.  Cohort Profile: The AMORIS cohort. , 2017, International journal of epidemiology.

[19]  C. Sotiriou,et al.  Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer , 2017, Modern Pathology.

[20]  Nirmesh Patel,et al.  PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer , 2016, Nature Medicine.

[21]  Franca Fraternali,et al.  Significant Differences in Physicochemical Properties of Human Immunoglobulin Kappa and Lambda CDR3 Regions , 2016, Front. Immunol..

[22]  H. Lee,et al.  Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[23]  M. Garnelo,et al.  Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma , 2015, Gut.

[24]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[25]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[26]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures in cancer and beyond. , 2014, Trends in immunology.

[27]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  K. Silina,et al.  Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue? , 2014, Cancer Immunology, Immunotherapy.

[29]  D. McMillan,et al.  The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer , 2013, British Journal of Cancer.

[30]  C. Slingluff,et al.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. , 2012, Cancer research.

[31]  C. Ostwald,et al.  Ex-vivo Clonally Expanded B Lymphocytes Infiltrating Colorectal Carcinoma Are of Mature Immunophenotype and Produce Functional IgG , 2012, PloS one.

[32]  J. Tímár,et al.  Prognostic impact of B-cell density in cutaneous melanoma , 2011, Cancer Immunology, Immunotherapy.

[33]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[34]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[35]  H. Komatsu [Antibody therapy in cancer]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.

[36]  S. Altiok,et al.  Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. , 2010, The Journal of clinical investigation.

[37]  K. Flaherty,et al.  Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers , 2009, Clinical Cancer Research.

[38]  F. Lund Cytokine-producing B lymphocytes-key regulators of immunity. , 2008, Current opinion in immunology.

[39]  Marie-Paule Lefranc,et al.  IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis , 2008, Nucleic Acids Res..

[40]  Erik Flemington,et al.  B-cell Receptor Activation Induces BIC/miR-155 Expression through a Conserved AP-1 Element* , 2008, Journal of Biological Chemistry.

[41]  A. Anastasi,et al.  Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells , 2007, BMC biotechnology.

[42]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Cyster,et al.  Chemokine Requirements for B Cell Entry to Lymph Nodes and Peyer's Patches , 2002, The Journal of experimental medicine.

[44]  C. Moratz,et al.  Regulator of G Protein Signaling 1 (RGS1) Markedly Impairs Giα Signaling Responses of B Lymphocytes , 2000, The Journal of Immunology.

[45]  D. Kipling,et al.  Assessment of B Cell Repertoire in Humans. , 2015, Methods in molecular biology.

[46]  A. Tan,et al.  Triple-negative breast cancer: molecular subtypes and new targets for therapy. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[47]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[48]  P. Musto,et al.  CD69 expression in B-cell chronic lymphocytic leukemia: a new prognostic marker ? , 2001, Haematologica.